![](images/graphics/blank.gif)
Progressive fibrosing interstitial lung diseases
-
Nintedanib reduces the rate of decline in forced vital capacity in patients with idiopathic pulmonary fbrosis (IPF), other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype and systemic sclerosis-associated ILD (SSc-ILD). The recommended dose of nintedanib is 150 mg twice daily (BID).
13p
vimackenziebezos
29-11-2021
14
0
Download
-
Fibrosing, non-idiopathic pulmonary fibrosis (non-IPF) interstitial lung diseases (fILDs) are a heterogeneous group of diseases characterized by a different amount of inflammation and fibrosis. Therapy is currently based on corticosteroids and/or immunomodulators.
9p
vimichigan2711
26-03-2021
11
2
Download
-
Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal fibrosing lung disease of unknown cause. The advent of anti-fibrotic medications known to slow disease progression has revolutionised IPF management in recent years.
8p
vimaine2711
26-03-2021
9
2
Download
CHỦ ĐỀ BẠN MUỐN TÌM
![](images/graphics/blank.gif)